文献速递MDS 与骨髓增殖性肿瘤

迈向骨髓增生异常综合征可测量残留病灶的概念化

Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2023-01-01

约90%的骨髓增生异常综合征(MDS)患者携带已知或疑似致癌的体细胞突变,临床分子国际预后评分系统已将诊断时二代测序确立为标准。本文总结当前证据与挑战,提出将可测量残留病灶(MRD)纳入MDS治疗及未来临床试验的概念框架。

要点

  • 约90%的MDS患者有已知或疑似致癌的体细胞突变。
  • 临床分子国际预后评分系统将诊断时二代测序确立为标准。
  • MRD在MDS中尚未被正式定义为生物标志物。

核心结论

  • 本文总结当前证据与挑战,并为将MRD纳入MDS治疗和未来临床试验提供概念框架。

研究设计与样本

  • 本文为综述,总结当前证据与挑战并提出概念框架。

主要发现

  • 约90%的MDS患者具有已知或疑似在恶性细胞中致癌的体细胞突变。
  • 临床分子国际预后评分系统的引入使MDS遗传风险分层发生实质演变,并将诊断时二代测序确立为标准。
  • 国际髓系肿瘤和急性白血病共识分类通过引入新的MDS/急性髓系白血病类别细化了MDS诊断标准。
  • 在急性和慢性白血病中,监测MRD历来用于定义缓解状态、改善复发预测和确定抗白血病药物疗效。
  • 与白血病不同,MDS中MRD评估(包括追踪患者特异性突变)尚未被正式定义为生物标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 90% of patients with myelodysplastic syndromes (MDSs) have somatic mutations that are known or suspected to be oncogenic in the malignant cells. The genetic risk stratification of MDSs has evolved substantially with the introduction of the clinical molecular international prognostic scoring system, which establishes next-generation sequencing at diagnosis as a standard of care. Furthermore, the International Consensus Classification of myeloid neoplasms and acute leukemias has refined the MDS diagnostic criteria with the introduction of a new MDS/acute myeloid leukemia category. Monitoring measurable residual disease (MRD) has historically been used to define remission status, improve relapse prediction, and determine the efficacy of antileukemic drugs in patients with acute and chronic leukemias. However, in contrast to leukemias, assessment of MRD, including tracking of patient-specific mutations, has not yet been formally defined as a biomarker for MDS. This article summarizes current evidence and challenges and provides a conceptual framework for incorporating MRD into the treatment of MDS and future clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schulz E, Aplan PD, Freeman SD, et al. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes. Blood Adv. 2023. PMID: 37267435. doi:10.1182/bloodadvances.2023010098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。